Suppr超能文献

凝血蛋白酶活性的体外与体内相关性:肝素的影响

In vitro and in vivo correlation of clotting protease activity: effect of heparin.

作者信息

Gitel S N, Stephenson R C, Wessler S

出版信息

Proc Natl Acad Sci U S A. 1977 Jul;74(7):3028-32. doi: 10.1073/pnas.74.7.3028.

Abstract

The thrombogenicity of three highly purified proteases (thrombin, activated Factor X, and activated Factor IX) was determined quantitatively in an animal model. The minimal amounts required to produce a standard score 4 thrombus were 1.1 nmol for thrombin, 0.12 nmol for activated Factor X, and 0.018 nmol for activated Factor IX. After the administration of heparin at 5, 10, and 20 units/kg in rabbits, the thrombogenicity of each of these proteases decreased progressively. The heparin-induced inhibition of thrombosis decreased in the order, activated Factor IX > activated Factor X > thrombin at each heparin concentration. These differences were statistically significant. These in vivo data provide support for the following hypotheses originally developed from in vitro experiments: (i) activation of the blood coagulation system, which proceeds through a cascade mechanism, incorporates biochemical amplification; (ii) the inhibition of activated Factor IX by antithrombin III in the presence of heparin is an important reaction in the prevention of thrombosis; (iii) less heparin is required to inhibit thrombosis prior to thrombin generation than afterward; (iv) an increase in the reactivity of antithrombin III reflects a decreased tendency to thrombosis while a decrease in this reactivity reflects an increased tendency to thrombosis.

摘要

在动物模型中对三种高度纯化的蛋白酶(凝血酶、活化的因子X和活化的因子IX)的血栓形成性进行了定量测定。产生标准4分血栓所需的最小量,凝血酶为1.1纳摩尔,活化的因子X为0.12纳摩尔,活化的因子IX为0.018纳摩尔。在兔中以5、10和20单位/千克给予肝素后,这些蛋白酶各自的血栓形成性逐渐降低。在每个肝素浓度下,肝素诱导的血栓形成抑制作用按活化的因子IX>活化的因子X>凝血酶的顺序降低。这些差异具有统计学意义。这些体内数据为最初从体外实验得出的以下假设提供了支持:(i)通过级联机制进行的血液凝固系统激活包含生化放大作用;(ii)在肝素存在下抗凝血酶III对活化的因子IX的抑制是预防血栓形成的重要反应;(iii)在凝血酶生成之前抑制血栓形成所需的肝素比之后少;(iv)抗凝血酶III反应性的增加反映血栓形成倾向降低,而这种反应性的降低反映血栓形成倾向增加。

相似文献

引用本文的文献

2
Factor IX(a) inhibitors: an updated patent review (2003-present).因子 IX(a)抑制剂:更新的专利审查(2003 年至今)。
Expert Opin Ther Pat. 2022 Apr;32(4):381-400. doi: 10.1080/13543776.2022.2026926. Epub 2022 Jan 17.
3
Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.激素避孕的绝经前妇女血浆因子 IXa 活性升高。
Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):266-274. doi: 10.1161/ATVBAHA.117.309919. Epub 2017 Nov 2.
4
Translation and Clinical Development of Antithrombotic Aptamers.抗血栓适体的翻译与临床开发
Nucleic Acid Ther. 2016 Jun;26(3):147-55. doi: 10.1089/nat.2015.0581. Epub 2016 Feb 16.
7
Mechanism of the anticoagulant action of heparin.肝素抗凝作用的机制。
Mol Cell Biochem. 1982 Oct 29;48(3):161-82. doi: 10.1007/BF00421226.

本文引用的文献

1
Anticoagulant therapy in surgery.外科手术中的抗凝治疗。
J Am Med Assoc. 1950 Feb 25;142(8):527-34. doi: 10.1001/jama.1950.02910260001001.
5
WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.内源性凝血瀑布序列
Science. 1964 Sep 18;145(3638):1310-2. doi: 10.1126/science.145.3638.1310.
7
Thrombosis in the presence of vascular stasis.血管淤滞时的血栓形成。
Am J Med. 1962 Nov;33:648-66. doi: 10.1016/0002-9343(62)90244-9.
8
Biologic assay of a thrombosis-inducing activity in human serum.
J Appl Physiol. 1959 Nov;14:943-6. doi: 10.1152/jappl.1959.14.6.943.
9
Quantitative aspects of antithrombin and heparin in plasma.血浆中抗凝血酶和肝素的定量分析
Am J Physiol. 1956 Mar;184(3):627-39. doi: 10.1152/ajplegacy.1956.184.3.627.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验